Limitations of the dorsal skinfold window chamber model in evaluating anti-angiogenic therapy during early phase of angiogenesis

Vascular Cell

Dietmar W Siemann¹  Brian S Sorg²  Jennifer A Lee³  Nikolett M Biel⁴ 

[1] Department of Radiation Oncology, University of Florida College of Medicine, 2000 SW Archer Road, Gainesville FL 32610, USA;Cancer Diagnosis Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Rockville MD 20852, USA;J. Crayton Pruitt Family Department of Biomedical Engineering, University of Florida, Biomedical Sciences Building, Gainesville FL 32610, USA;Department of Pharmacology and Therapeutics, University of Florida College of Medicine, Cancer and Genetics Research Complex, 2033 Mowry Rd., Gainesville FL 32610, USA

关键词: Vascular endothelial growth factor;    Dorsal skinfold window chamber model;    Anti-angiogenic therapy;    Angiopoietin-2;    Angiogenesis;   

Others  :  1131006
DOI  :  10.1186/2045-824X-6-17

 received in 2014-03-30, accepted in 2014-07-27,  发布年份 2014

【 摘 要 】

Background

Angiogenesis is an essential process during tumor development and growth. The murine dorsal skinfold window chamber model has been used for the study of both tumor microvasculature and other vascular diseases, including the study of anti-angiogenic agents in cancer therapy. Hyperspectral imaging of oxygen status of the microvasculature has not been widely used to evaluate response to inhibition of angiogenesis in early tumor cell induced vascular development. This study demonstrates the use of two different classes of anti-angiogenic agents, one targeting the Vascular Endothelial Growth Factor (VEGF) pathway involved with vessel sprouting and the other targeting the Angiopoietin/Tie2 pathway involved in vascular destabilization. Studies evaluated the tumor microvascular response to anti-angiogenic inhibitors in the highly angiogenic renal cell carcinoma induced angiogenesis model.

Methods

Human renal cell carcinoma, Caki-2 cells, were implanted in the murine skinfold window chamber. Mice were treated with either VEGF pathway targeted small molecule inhibitor Sunitinib (100 mg/kg) or with an anti-Ang-2 monoclonal antibody (10 mg/kg) beginning the day of window chamber surgery and tumor cell implantation. Hyperspectral imaging of hemoglobin saturation was used to evaluate both the development and oxygenation of the tumor microvasculature. Tumor volume over time was also assessed over an 11-day period post surgery.

Results

The window chamber model was useful to demonstrate the inhibition of angiogenesis using the VEGF pathway targeted agent Sunitinib. Results show impairment of tumor microvascular development, reduced oxygenation of tumor-associated vasculature and impairment of tumor volume growth compared to control. On the other hand, this model failed to demonstrate the anti-angiogenic effect of the Ang-2 targeted agent. Follow up experiments suggest that the initial surgery of the window chamber model may interfere with such an agent thus skewing the actual effects on angiogenesis.

Conclusions

Results show that this model has great potential to evaluate anti-VEGF, or comparable, targeted agents; however the mere protocol of the window chamber model interferes with proper evaluation of Ang-2 targeted agents. The limitations of this in vivo model in evaluating the response of tumor vasculature to anti-angiogenic agents are discussed.

【 授权许可】

   
2014 Biel et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

Figure 6.

Figure 7.

Figure 8.

【 参考文献 】

• [1]Folkman J: Tumor angiogenesis: therapeutic implications. New Eng J Med 1971, 285:1182-1186.
• [2]Augustin HG, Koh GY, Thurston G, Alitalo K: Control of vascular morphogenesis and homeostasis through the angiopoietin-Tie system. Nat Rev Mol Cell Biol 2009, 10:165-177.
• [3]Weis SM, Cheresh DA: Tumor angiogenesis: molecular pathways and therapeutic targets. Nat Med 2011, 17:1359-1367.
• [4]Loges S, Schmidt T, Carmeliet P: Mechanisms of resistance to anti-angiogenic therapy and development of third-generation anti-angiogenic drug candidates. Genes Cancer 2010, 1:12-25.
• [5]Bergers G, Hanahan D: Modes of resistance to anti-angiogenic therapy. Nat Rev 2008, 8:592-603.
• [6]Gerald D, Chintharlapalli S, Augustin HG, Benjamin LE: Angiopoietin-2: an attractive target for improved antiangiogenic tumor therapy. Cancer Res 2013, 73:1649-1657.
• [7]Moy AJ, White SM, Indrawan ES, Lotfi J, Nudelman MJ, Costantini SJ, Agarwal N, Jia W, Kelly KM, Sorg BS, Choi B: Wide-field functional imaging of blood flow and hemoglobin oxygen saturation in the rodent dorsal window chamber. Microvasc Res 2011, 82:199-209.
• [8]Palmer GM, Fontanella AN, Shan S, Hanna G: In vivo optical molecular imaging and analysis in mice using dorsal window chamber models applied to hypoxia, vasculature and fluorescent reporters. Nat Prot 2011, 6:1355-1366.
• [9]Li CY, Shan S, Huang Q, Braun RD, Lanzen J, Hu K, Lin P, Dewhirst MW: Initial stages of tumor cell-induced angiogenesis: evaluation via skin window chambers in rodent models. J Natl Cancer Inst 2000, 92:143-147.
• [10]Laschke MW, Menger MD: In vitro and in vivo approaches to study angiogenesis in the pathophysiology and therapy of endometriosis. Hum Reprod Update 2007, 13:331-342.
• [11]Borgstrom P, Gold DP, Hillan KJ, Ferrara N: Importance of VEGF for breast cancer angiogenesis in vivo: implications from intravital microscopy of combination treatments with an anti-VEGF neutralizing monoclonal antibody and doxorubicin. Anticancer Res 1999, 19:4203-4214.
• [12]Borgstrom P, Hillan KJ, Sriramarao P, Ferrara N: Complete inhibition of angiogenesis and growth of microtumors by anti-vascular endothelial growth factor neutralizing antibody: novel concepts of angiostatic therapy from intravital videomicroscopy. Cancer Res 1996, 56:4032-4039.
• [13]Borgstrom P, Bourdon MA, Hillan KJ, Sriramarao P, Ferrara N: Neutralizing anti-vascular endothelial growth factor antibody completely inhibits angiogenesis and growth of human prostate carcinoma micro tumors in vivo. Prostate 1998, 35:1-10.
• [14]Yuan F, Chen Y, Dellian M, Safabakhsh N, Ferrara N, Jain RK: Time-dependent vascular regression and permeability changes in established human tumor xenografts induced by an anti-vascular endothelial growth factor/vascular permeability factor antibody. Proc Natl Acad Sci USA 1996, 93:14765-14770.
• [15]Sorg BS, Moeller BJ, Donovan O, Cao Y, Dewhirst MW: Hyperspectral imaging of hemoglobin saturation in tumor microvasculature and tumor hypoxia development. J Biomed Opt 2005., 10044004-1-11
• [16]Hardee ME, Dewhirst MW, Agarwal N, Sorg BS: Novel imaging provides new insights into mechanisms of oxygen transport in tumors. Curr Mol Med 2009, 9:435-441.
• [17]Dedeugd C, Wankhede M, Sorg BS: Multimodal optical imaging of microvessel network convective oxygen transport dynamics. Appl Opt 2009, 48:D187-D197.
• [18]Wankhede M, Agarwal N, Fraga-Silva RA, Dedeugd C, Raizada MK, Oh SP, Sorg BS: Spectral imaging reveals microvessel physiology and function from anastomoses to thromboses. J Biomed Opt 2010, 15:011111.
• [19]Dewhirst MW, Cao Y, Li CY, Moeller B: Exploring the role of HIF-1 in early angiogenesis and response to radiotherapy. Radiother Oncol 2007, 83:249-255.
• [20]Wankhede M, Dedeugd C, Siemann DW, Sorg BS: In vivo functional differences in microvascular response of 4 T1 and Caki-1 tumors after treatment with OXi4503. Oncol Rep 2010, 23:685-692.
• [21]Terman DS, Viglianti BL, Zennadi R, Fels D, Boruta RJ, Yuan H, Dreher MR, Grant G, Rabbani ZN, Moon E, Lan L, Eble J, Cao Y, Sorg B, Ashcraft K, Palmer G, Telen MJ, Dewhirst MW: Sickle erythrocytes target cytotoxics to hypoxic tumor microvessels and potentiate a tumoricidal response. PLoS One 2013, 8:e52543.
• [22]Park SO, Wankhede M, Lee YJ, Choi EJ, Fliess N, Choe SW, Oh SH, Walter G, Raizada MK, Sorg BS, Oh SP: Real-time imaging of de novo arteriovenous malformation in a mouse model of hereditary hemorrhagic telangiectasia. J Clin Invest 2009, 119:3487-3496.
• [23]Choe SW, Acharya AP, Keselowsky BG, Sorg BS: Intravital microscopy imaging of macrophage localization to immunogenic particles and co-localized tissue oxygen saturation. Acta Biomater 2010, 6:3491-3498.
• [24]Auerbach R: Models of Angiogenesis. In Angiogenesis: An Integrative Approach From Science To Medicine. Edited by Folkman J, Figg WD. New York: Springer Science + Business Media, LLC; 2008:299-312.
• [25]Kampfer H, Pfeilschifter J, Frank S: Expressional regulation of angiopoietin-1 and -2 and the tie-1 and -2 receptor tyrosine kinases during cutaneous wound healing: a comparative study of normal and impaired repair. Lab Invest 2001, 81:361-373.
• [26]Staton CA, Valluru M, Hoh L, Reed MW, Brown NJ: Angiopoietin-1, angiopoietin-2 and Tie-2 receptor expression in human dermal wound repair and scarring. Br J Dermatol 2010, 163:920-927.
• [27]Ebos JM, Lee CR, Kerbel RS: Tumor and host-mediated pathways of resistance and disease progression in response to antiangiogenic therapy. Clin Cancer Res 2009, 15:5020-5025.
• [28]Goodman VL, Rock EP, Dagher R, Ramchandani RP, Abraham S, Gobburu JV, Booth BP, Verbois SL, Morse DE, Liang CY, Chidambaram N, Jiang JX, Tang S, Mahjoob K, Justice R, Pazdur R: Approval summary: sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma. Clin Cancer Res 2007, 13:1367-1373.
• [29]Molnar N, Siemann DW: Inhibition of endothelial/smooth muscle cell contact loss by the investigational angiopoietin-2 antibody MEDI3617. Microvasc Res 2012, 83:290-297.
• [30]Roviezzo F, Tsigkos S, Kotanidou A, Bucci M, Brancaleone V, Cirino G, Papapetropoulos A: Angiopoietin-2 causes inflammation in vivo by promoting vascular leakage. J Pharmacol Exp Ther 2005, 314:738-744.
• [31]Fiedler U, Reiss Y, Scharpfenecker M, Grunow V, Koidl S, Thurston G, Gale NW, Witzenrath M, Rosseau S, Suttorp N, Sobke A, Herrmann M, Preissner KT, Vajkoczy P, Augustin HG: Angiopoietin-2 sensitizes endothelial cells to TNF-alpha and has a crucial role in the induction of inflammation. Nat Med 2006, 12:235-239.
• [32]McDonald DM: Angiogenesis and Vascular Remodeling in Inflammation and Cancer: Biology and Architecture of the Vasculature. In Angiogenesis: An Integrative Approach From Science To Medicine. Edited by Folkman J, Figg WD. New York: Springer Science + Business Media, LLC; 2008:17-34.
• [33]Fiedler U, Augustin HG: Angiopoietins: a link between angiogenesis and inflammation. Trends Immunol 2006, 27:552-558.
• [34]Lowenstein CJ, Morrell CN, Yamakuchi M: Regulation of Weibel-Palade body exocytosis. Trends Cardiovasc Med 2005, 15:302-308.
• [35]Fiedler U, Scharpfenecker M, Koidl S, Hegen A, Grunow V, Schmidt JM, Kriz W, Thurston G, Augustin HG: The Tie-2 ligand angiopoietin-2 is stored in and rapidly released upon stimulation from endothelial cell Weibel-Palade bodies. Blood 2004, 103:4150-4156.
• [36]Rondaij MG, Bierings R, Kragt A, van Mourik JA, Voorberg J: Dynamics and plasticity of Weibel-Palade bodies in endothelial cells. Arterioscler Thromb Vasc Biol 2006, 26:1002-1007.
• [37]Carmeliet P: Angiogenesis in life, disease and medicine. Nat 2005, 438:932-936.